Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dynavax Technologies Corporation
Dynavax Enters Into Supply and Option Agreement for Development of Universal Influenza Vaccine
August 13th, 2008
Dynavax Technologies Corporation (Nasdaq:DVAX) announced an agreement with Novartis Vaccines and Diagnostics, Inc. for the supply and development, and possible commercialization, of Dynavax's novel Universal Influenza Vaccine in collaboration with Novartis. Under the agreement Novartis will provide Dynavax a supply of trivalent influenza vaccine, an essential component of Dynavax's Universal Influenza Vaccine, for both clinical trial use and vaccine sales. Novartis receives an exclusive option to negotiate a Joint Development and Commercialization Agreement with Dynavax. "This agreement with one of the world's leading manufacturers and innovators in influenza vaccines...
Source: Vaccine Weekly (2008-08-13)
|
